Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor and Radiation Therapy in Newly-Diagnosed Pediatric DIPG and HGG
NCT05099003Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2022
- Primary completion
- Sep 2027
- Countries
- 4
01
Overview
A Phase 2 trial of selinexor in diffuse intrinsic pontine glioma (DIPG), glioma, sponsored by National Cancer Institute. Started May 2022; status: active, not recruiting.
02
Drugs
selinexor
03
Conditions
diffuse intrinsic pontine glioma (DIPG)glioma
Beyond the preview
Go deeper on NCT05099003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05099003.